Evidence map›Paper›PMID 26500897›Full record

ArticleJournal of clinical and diagnostic research : JCDR2015

Serum Adenosine Deaminase as Inflammatory Marker in Rheumatoid Arthritis.

Kiranmayi S Vinapamula, Srinivasarao V L N Pemmaraju, Siddartha Kumar Bhattaram, Aparna R Bitla, Suchitra M Manohar

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical and diagnostic research : JCDR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Markers of inflammation in obese pregnant women: Adenosine deaminase and high sensitive C - reactive protein.European journal of obstetrics & gynecology and reproductive biology: X · 2022
    Article
  9. Article
  10. Article
  11. Adenosine and Inflammation: Here, There and Everywhere.International journal of molecular sciences · 2021
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Serum Adenosine Deaminase as a Useful Marker to Estimate Coronary Artery Calcification in Type 2 Diabetes Mellitus Patients.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Kiranmayi S VinapamulaAssistant Professor, Department of Biochemistry, Sri Venkateswara Institute of Medical Sciences , Tirupati, Andhra Pradesh, India .
Srinivasarao V L N PemmarajuProfessor and Head, Department of Biochemistry, Sri Venkateswara Institute of Medical Sciences , Tirupati, Andhra Pradesh, India .
Siddartha Kumar BhattaramProfessor, Department of Medicine, Sri Venkateswara Institute of Medical Sciences , Tirupati, Andhra Pradesh, India .
Aparna R BitlaAssociate Professor, Department of Biochemistry, Sri Venkateswara Institute of Medical Sciences , Tirupati, Andhra Pradesh, India .
Suchitra M ManoharAssociate Professor, Department of Biochemistry, Sri Venkateswara Institute of Medical Sciences , Tirupati, Andhra Pradesh, India .
Sri Venkateswara Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRheumatoid arthritis (RA) is a prototypical inflammatory joint disease. The degree of inflammation is reflected in the extent of joint damage, which further has influence on the quality of life of patients with RA, including risk of atherosclerosis. Hence, besides clinical indices, estimation of degree of inflammation using biochemical markers helps in effecting optimum treatment strategies. C-reactive protein (CRP) is established as an inflammatory marker in patients with RA. Adenosine deaminase (ADA), an enzyme of purine metabolism is considered as a marker of cell mediated immunity and has also been suggested as a marker of inflammatory process in RA. The present study attempts to study the efficacy of serum ADA activity as an inflammatory marker in RA. MATERIALS AND

methodsForty six RA patients and forty six age and sex matched healthy controls were included in the study. ADA activity and high sensitivity C-reactive protein (hsCRP) levels in serum were measured in all the subjects. Statistical analyses were done using Medcalc statistical software version 12.2.2.

resultsADA activity and hsCRP levels were increased in RA patients compared to controls (p<0.0001 and 0.0001 respectively). Significant positive correlation was obtained between hsCRP and ADA in patients (r=0.316, p=0.033). Receiver operating characteristic (ROC) curve analysis revealed statistically significant area under curve (AUC) for ADA that is comparable to that obtained for hsCRP (0.776, p<0.0001 for ADA, 0.726, p<0.0001 for hsCRP). Similar diagnostic utility was obtained with ROC generated cut-off value of 25.3 IU/L (82.6% sensitivity and 65.2% specificity) and with control mean value of 23.48 IU/L (86.96% sensitivity and 54.35% specificity) for ADA.

conclusionFindings of the present study indicate the importance of ADA as a marker of inflammation. Considering the higher sensitivity obtained, we propose control mean (23.48 IU/L) as a cut-off for serum ADA activity as an inflammatory marker. Owing to the simplicity and also the cost effectiveness of ADA assay, ADA may be recommended as a marker of inflammation in patients with RA. However, further larger and well controlled studies are needed to establish its role as inflammatory marker.

Indexed as

ADAAutoimmune diseaseInflammationInflammatory joint disease

Identifiers

PMID26500897
PMCPMC4606226
OpenAlexW2413812514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.